Citeline Podcasts

Citeline Podcasts

How Senti Bio's Programmable Cell Therapy Tackles AML's Toxicity Problem

Jan 27, 2026 · 33m

Listen to Episode

✨ AI Summary

Senti Bio CEO discusses programmable cell therapy for AML toxicity.
SENTI-202 shows 50% response rate in Phase 1 AML trial.
Phase 1 data reveals 39% complete remission with low toxicity.

Guests on This Episode

researcher · 2 podcast appearances

More from Citeline Podcasts

Scrip's Five Must-Know Things - Oct. 13, 2026

Oct 13, 2026 · 16m

Strategic Intent: Celebrity Marketing In The Age Of Promo Crackdown

Oct 13, 2026 · 26m

Drug Fix: US FDA’s Peptide Drama, More Transparency, Ibogaine Clinical Trial Plans

Oct 9, 2026 · 41m

Off-Patent, On Record: Navigating The Financial Strategy Behind Litigation With Sandoz’s Julia Pike

Oct 6, 2026 · 24m

View all episodes →